Status:
COMPLETED
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
Lead Sponsor:
Jonathan Baghdadi
Collaborating Sponsors:
Centers for Disease Control and Prevention
Conditions:
Pneumonia
Pneumonia, Viral
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this prospective randomized study is to improve antibiotic use among hospitalized patients with suspected pneumonia. An alert was built into the electronic health record to guide use of di...
Detailed Description
Low-risk patients with viral pneumonia do not benefit from and may be harmed by antibiotic therapy. In this study, an alert will appear in the electronic health record of patients undergoing molecular...
Eligibility Criteria
Inclusion
- Adult patients admitted to the University of Maryland Medical Center or University of Maryland Medical Center-Midtown Campus who are prescribed antibiotics for suspected community-acquired respiratory infection.
- Protocol-based diagnostic testing supports possible viral infection, either by positive molecular test or low procalcitonin value.
Exclusion
- Hospitalization for \>72 hours prior to protocol-based diagnostic testing.
- Previous molecular testing for viral infection during the same hospital encounter.
- Severely immunosuppressed, defined as having hematologic malignancy, solid organ tumor on chemotherapy, or solid organ transplant on immunosuppression
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2025
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT05976581
Start Date
November 1 2023
End Date
May 31 2025
Last Update
July 17 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland Medical Center - Midtown Campus
Baltimore, Maryland, United States, 21201
2
University of Maryland Medical Center
Baltimore, Maryland, United States, 21201